Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 12, 2016
Context: This filing serves as a Notice of Special General Meeting of Shareholders and Proxy Statement. The meeting is scheduled for February 16, 2016, in Tel Aviv, Israel. The primary purpose is to solicit shareholder votes on the election of a new external director and an increase in authorized share capital.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance filing rather than a financial report.
| Metric | Value |
|---|---|
| Outstanding Ordinary Shares (as of Jan 11, 2016) | 127,114,294 |
| Current Authorized Share Capital | NIS 2,000,000 (200,000,000 shares) |
| Proposed Authorized Share Capital | NIS 3,000,000 (300,000,000 shares) |
| Shares Available for Future Issuance | Approx. 35,742,000 |
Material Changes and Proposals
The filing outlines two specific proposals to be voted upon by shareholders:
- Election of External Director: To elect Ms. Nurit Benjamini as an external director for a three-year term. This is necessary to comply with the Israeli Companies Law, which requires at least two external directors. The company currently has only one following the passing of former director Alicia Rotbard.
- Increase in Authorized Share Capital: To increase authorized capital from NIS 2,000,000 (200 million shares) to NIS 3,000,000 (300 million shares). The Board states this is necessary to ensure sufficient capital is available for future opportunities, including acquisitions, capital raises, or stock option grants, without undue delay.
Outlook, Risks, and Management Commentary
Management Commentary: The Board of Directors recommends a vote "FOR" both proposals. They assert that Ms. Benjamini possesses the requisite "financial and accounting expertise" and independence to serve as an external director. Regarding the capital increase, management emphasizes the need for flexibility to pursue strategic opportunities.
Risks and Contingencies:
- Quorum Risk: A quorum requires shareholders holding at least 25% of voting power. If not met within 30 minutes, the meeting will be adjourned to the next business day.
- Voting Thresholds: The election of the external director requires a majority vote of shares present, subject to specific protections for non-controlling shareholders (either a majority of non-controlling votes or less than 2% of total voting rights voting against).
- Regulatory Compliance: The filing notes the company is a foreign private issuer and is exempt from certain U.S. proxy rules, though it adheres to Israeli Companies Law requirements.
Investor Verification Checklist
- Verify the Record Date for voting eligibility is January 18, 2016 (close of business New York time).
- Confirm the meeting date and time: February 16, 2016, at 10:00 a.m. Israel time.
- Review Ms. Nurit Benjamini's background to confirm her independence and lack of conflicts of interest as detailed in the proxy statement.
- Assess the impact of the proposed 50% increase in authorized shares on potential future dilution.
- Check for any "Position Statements" submitted by shareholders by the February 7, 2016 deadline, which may be filed on Form 6-K.